

## SYNTHESIS OF BENZOXOLANE PROSTACYCLIN ANALOGUE


Sachio Mori\* and Shozo Takechi

Shionogi Research Laboratories, Shionogi &amp; Co., Ltd., Fukushima-ku,


Osaka 553, Japan

**Abstract** — Benzoxolane prostacyclin analogue ((±)-1) was synthesized with key steps involving regio- and stereocontrolled carbon-carbon bond formation using allylic phosphate (17) and stabilized copper reagent derived from 15, followed by intramolecular selenoetherification leading to cyclopentanobenzoxolane (19).

The preceding paper reported the synthesis of benzodioxane prostacyclin analogue ((±)-3),<sup>1</sup> which showed a different profile in terms of biological activities compared with its isomers, benzopyran- 4 and benzindene prostacyclin mimic 5.<sup>2</sup> This suggested that transformation of the central ring might be an attractive method for modulating biological activities, and we carried out another study along this line. Here we report the synthesis of structurally more rigid benzoxolane prostacyclin analogue ((±)-1), an isomer of benzcarbacyclin derivative (2).<sup>3</sup>




Our synthetic plan shown in Scheme 1, involves the preparation of 4-phenyl-2-cyclopenten-1-ol derivative (8), and its conversion into cyclopentanobenzoxolane (9) by selenoetherification. We assumed that 8 could



Scheme 1

be prepared favorably by a regio- and stereocontrolled carbon-carbon bond formation between *o*-metalated phenyl ether (**6**) and allylic ester (**7**), while introduction of the propenyl group to C<sub>12</sub> (PG numbering) of **9**, and subsequent extension of  $\alpha$ - and  $\omega$ -side chains were expected to afford target compound ( $\pm$ )-**1**. We first concentrated on model study of carbon-carbon bond formation using organocopper and allylic ester<sup>4</sup> for obtaining **8** (Table 1). Homocuprate (**13a**) was found to react with allylic acetate (**10a**) preferentially in an S<sub>N</sub>2 manner to give the desired product (**11**) in 49% yield based on **10a**, but the yield based on **13a** was only 24%. Therefore we examined various phenylcopper reagents and allylic esters, in order to increase the yield and minimize reagent loss. Trials with phenylcopper itself (Entry 2) or its BF<sub>3</sub>·OEt<sub>2</sub> complex (Entry 3) did not work, but combinations of stabilized phenylcoppers<sup>5</sup> and active allylic esters (Entries 6-12) led to greatly improved results, although a small amount of S<sub>N</sub>2' product (**12**) (Entries 8, 11) was sometimes obtained. The best result was achieved by the combination of allylic phosphate (**10e**)<sup>6</sup> and PhCu·2.5P(NMe<sub>2</sub>)<sub>3</sub> **13f** to give **11** in 73% and 61% yield based on **10e** and **13f**, respectively, with excellent S<sub>N</sub>2/S<sub>N</sub>2' selectivity (Entry 12).

Table 1. Reaction of organocopper reagents with allylic esters



R<sup>5</sup>  
 a: MeCO  
 b: 2,4-Cl<sub>2</sub>-PhCO  
 c: C<sub>6</sub>F<sub>5</sub>CO  
 d: CF<sub>3</sub>CO  
 e: (EtO)<sub>2</sub>PO

Copper reagents **13**

a: Ph<sub>2</sub>CuLi  
 b: PhCu  
 c: PhCu·BF<sub>3</sub>·OEt<sub>2</sub> (1:2)  
 d: PhCu-P(n-Bu)<sub>3</sub> (1:1.2)  
 e: PhCu-P(n-Bu)<sub>3</sub> (1:2.4)  
 f: PhCu-P(NMe<sub>2</sub>)<sub>3</sub> (1:2.5)  
 g: Ph(CN)CuLi

Entry	Subst. <b>10</b>	Reag. <b>13</b>	Temp. (°C)	Time <sup>a)</sup> (h)	Reag./Yield <sup>b)</sup> Subst. (%)	<b>11</b> / <b>12</b> <sup>c)</sup>
1	a	a	-40 $\nearrow$ 0	1.5	2 49 (12)	>20:1
2	a	b	-70 $\nearrow$ -20	1	2 0 (0)	--
3	a	c	-70 $\nearrow$ -20	1	2 0 (0)	--
4	a	d	-70 $\nearrow$ rt	o.n. <sup>d)</sup>	2 trace	--
5	b	d	-20 $\nearrow$ 0	o.n.	2 39 (20)	>20:1
6	c	d	-20 $\nearrow$ -10	3	2 67 (34)	>20:1
7	d	d	-20 $\nearrow$ -10	3	2 67 (34)	>20:1
8	e	d	-20 $\nearrow$ -10	3	2 87 (44)	7:1
9	d	e	-20 $\nearrow$ -10	o.n.	1.2 34 (28)	>20:1
10	d	e	-20 $\nearrow$ -10	2	1.2 59 (49)	>20:1
11	e	e	-20 $\nearrow$ -10	2	1.2 69 (58)	13:1
12	e	f	-20	1.5	1.2 73 (61)	>20:1
13	d	g	-15 $\nearrow$ rt	o.n.	3 47 (16)	2:3


<sup>a)</sup> After reaching the final temperature.

<sup>b)</sup> Yields in parentheses are based on phenyl group(s) in reagents.

<sup>c)</sup> The ratio was determined by <sup>1</sup>H-nmr analysis.

<sup>d)</sup> Overnight

Having reached a practical solution for the carbon-carbon bond formation, we embarked on the synthesis of ( $\pm$ )-**1**, with the results given in Scheme 2. Beginning with methyl 4-hydroxyphenylacetate (**14**), four-step conversion, namely, bromination, protection of the hydroxy group as THP ether, reduction of the ester to the alcohol, and its protection with the MEM group, afforded *o*-bromophenyl ether (**15**), one of the components of the key intermediate (**18**). The other component, the allylic phosphate (**17**), was prepared from the known allylic sulfide (**16**) via silylation, oxidation to the sulfoxide, rearrangement to the allylic alcohol, and esterification. We chose **17** bearing a bulkier *t*-butyldiphenylsilyloxy group at  $\delta$ -position instead of **10e**, which we expected would induce further improvement in S<sub>N</sub>2/S<sub>N</sub>2' ratio. As expected, the reaction between **17** and the hexamethyl phosphorous triamide-stabilized organocopper



a) NBS (1 eq.)/DMF (66%). b) DHP, PPTS/CH<sub>2</sub>Cl<sub>2</sub>. c) LiAlH<sub>4</sub>/Et<sub>2</sub>O. d) MEMCl, *i*-Pr<sub>2</sub>NEt/CH<sub>2</sub>Cl<sub>2</sub> (b, c, d 88%). e) *t*-BuPh<sub>2</sub>SiCl, DMAP/DMF. f) mCPBA (1 eq.)/CH<sub>2</sub>Cl<sub>2</sub>, -70°C. g) Ph<sub>3</sub>P (1.47 eq.)/MeOH-PhMe, 65°C, overnight (e, f, g 88%). h) *n*-BuLi (1 eq.)/HMPA-THF, -20°C; (EtO)<sub>2</sub>POCl (1.5 eq.) (63%). i) i. 15 (2 eq.), *n*-BuLi (2 eq.)/THF, -70°C, 15 min; ii. CuBr·SMe<sub>2</sub> (2 eq.), (Me<sub>2</sub>N)<sub>3</sub>P (5 eq.)/THF, -70°C, add. over 20 min, additional 15 min, and then -30°C, 40 min; iii. 17 (1 eq.)/THF, -20 - -30°C, add. over 40 min, and then -20°C, 50 min (86% based on 17). j) PPTS/MeOH (72%). k) PhSeBr (1.3 eq.), propylene oxide (5 eq.)/CH<sub>2</sub>Cl<sub>2</sub>, 0°C, and then room temperature, overnight (95%). l) *n*-Bu<sub>3</sub>SnCH<sub>2</sub>CH=CH<sub>2</sub> (3 eq.)/PhH, h $\nu$ , 5 h (60%). m) TMSCl (4 eq.), NaI (4 eq.)/MeCN, add. in equal two portions at 0 and 20 min; -15°C, total 50 min, aq. NH<sub>4</sub>Cl quench (85%). n) i. (COCl)<sub>2</sub> (2 eq.), DMSO (4 eq.)/CH<sub>2</sub>Cl<sub>2</sub>, -78°C; ii. 21 (1 eq.); iii. Et<sub>3</sub>N (4 eq.), -78°C  $\nearrow$  -20°C. o) NaClO<sub>2</sub> (5 eq.), Me<sub>2</sub>C=CHMe (28 eq.), NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O (3.75 eq.)/*t*-BuOH-H<sub>2</sub>O, room temperature, 10 min. p) CH<sub>2</sub>N<sub>2</sub>/Et<sub>2</sub>O (n, o, p 73%). q) PhSeCl (1.1 eq.)/CCl<sub>4</sub>, 0°C, 10 min; Py, 30% H<sub>2</sub>O<sub>2</sub>, 0°C, and then room temperature, 1 h (77%). r) CsOAc (3 eq.), 18-Crown-6 (1 eq.)/PhMe, reflux, 19 h (86%). s) OsO<sub>4</sub> (0.1 eq.), Me<sub>3</sub>NO (2 eq.)/MeCOMe-THF-H<sub>2</sub>O, 4 h, room temperature. t) NaIO<sub>4</sub> (2 eq.)/DME-H<sub>2</sub>O, room temperature, overnight (s, t 61%). u) (MeO)<sub>2</sub>POCH<sub>2</sub>COC<sub>5</sub>H<sub>11</sub><sup>n</sup> (1.5 eq.), NaH (1.3 eq.)/THF, room temperature, 20 min; 23, room temperature, 40 min (95%). v) CeCl<sub>3</sub>·7H<sub>2</sub>O (1 eq.), NaBH<sub>4</sub> (1 eq.)/THF-MeOH, 0°C, 5 min (24 61%, 25 36%). w) *n*-Bu<sub>4</sub>NF/THF (67%). x) aq. NaOH-MeOH (72%).

Scheme 2

prepared from 15 went satisfactorily and exclusively gave 18 in 86% yield based on 17 (i. 15 2 eq., *n*-BuLi 2 eq./THF, -70°C; ii. CuBr·SMe<sub>2</sub> 2 eq., (Me<sub>2</sub>N)<sub>3</sub>P 5 eq./THF, -70°C and then -30°C; iii. 17 1 eq./THF, add. at -20 - -30°C and then -20°C).

In the next key step, the phenol obtained by deprotection of the THP group in 18 was subjected to seleno-etherification.<sup>7</sup> We found that a combination of phenylselenenyl bromide and propylene oxide<sup>8</sup> worked

nicely to give the desired cyclopentanobenzoxolane (**19**) in excellent yield (95%). The propenyl group was introduced by trapping the radical formed from **19** with allyltin,<sup>1</sup> which was followed by deprotection of the MEM group to afford the alcohol (**21**). The latter process was problematic at the beginning. Thus treatment of **20** with ZnBr<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub><sup>9</sup> led to formation of tetracyclic compound (**26**,<sup>10</sup> 69%) with only a small amount of **21** (12%), while another procedure, namely, TMSCl, NaI/MeCN treatment and subsequent quenching with aq. NaCl gave the dimeric compound (**27**) as the major product (72%). Eventually, we were able to solve the problem by replacing the quenching medium of aq. NaCl with weakly acidic aq. NH<sub>4</sub>Cl to obtain **21** in good yield (85%).

Further conversion of alcohol (**21**) to ester (**22**) by stepwise oxidation to the acid, and its esterification completed the formation of the  $\alpha$ -side chain, leaving construction of the  $\omega$ -side chain as the final task. The propenyl group in **22** was transformed into a formyl group to obtain the versatile intermediate (**23**) by sequential procedures including addition of phenylselenenyl chloride and oxidative elimination to the allylic chloride in one pot, its conversion into the allylic acetate, and cleavage of the double bond. Extension of the  $\omega$ -side chain was performed by the Horner-Emmons reaction to obtain the (E)-enone, which was reduced to a mixture of allylic alcohols (**24**, 15 $\alpha$ -OH, less polar, 61%) and (**25**, 15 $\beta$ -OH, more polar, 36%).<sup>11</sup> Finally, deprotection via the methyl ester furnished benzoxolane prostacyclin analogue (( $\pm$ )-**1**).<sup>12</sup>

Compound ( $\pm$ )-**1** was found to be far less active in inhibiting platelet aggregation (IC<sub>50</sub> = 189  $\mu$ M, ADP, rabbit PRP) than benzodioxane prostacyclin analogue (( $\pm$ )-**3a**) and non-cytoprotective.

#### ACKNOWLEDGEMENT

We thank Drs. K. Uchida and M. Doteuchi for testing the biological activities.

#### REFERENCES AND NOTES

1. S. Mori and S. Takechi, the preceding paper in this issue.
2. P. A. Aristoff, A. W. Harrison, and A. M. Huber, *Tetrahedron Lett.*, 1984, **25**, 3955 and references cited therein; P. A. Aristoff, A. W. Harrison, P. D. Johnson, and A. Robert, 'Advances in Prostaglandin, Thromboxane and Leukotriene Research,' Vol. 15, ed. by O. Hayaishi and S. Yamamoto, Raven Press, New York, 1985, p. 275.
3. K. Iseki, K. Hyoto, and Y. Hayashi, JP-88190852 (Aug. 8, 1988) (*Chem. Abstr.*, 1989, **110**, 57403c).
4. H. L. Goering and S. S. Kantner, *J. Org. Chem.*, 1984, **49**, 422; R. W. Rickards and H. Rönneberg, *ibid.*, 1984, **49**, 572; J. Kallmerten, *Tetrahedron Lett.*, 1984, **25**, 2843.
5. M. Suzuki, T. Suzuki, T. Kawagishi, Y. Morita, and R. Noyori, *Isr. J. Chem.*, 1984, **24**, 118.
6. S. Araki and Y. Butsugan, *Chemistry Lett.*, 1982, 177.

7. D. L. J. Clive, G. Chittattu, N. J. Curtis, W. A. Kiel, and C. K. Wong, *J. Chem. Soc., Chem. Comm.*, 1977, 725; A. G. Schultz and P. Sundararaman, *J. Org. Chem.*, 1984, **49**, 2455; A. G. Schultz, J. J. Napier, and P. Sundararaman, *J. Am. Chem. Soc.*, 1984, **106**, 3590.
8. Usage of phenylselenenyl chloride itself led to a modest yield (43%) partly because of deblocking of the hydroxy-protecting group(s) by the generating acid, which was very severe in the case of selenenyl bromide, while a combination of propylene oxide and selenenyl chloride failed to improve the yield.
9. E. J. Corey, J.-L. Gras, and P. Ulrich, *Tetrahedron Lett.*, 1976, 809.
10. The same type of isochroman formation assisted by  $TiCl_4$  has been reported by D. L. Mohler and W. Thompson, *Tetrahedron Lett.*, 1987, **28**, 2567.
11. The 11-hydroxy-protecting group in **24** and **25** was removed separately to give the methyl ester of ( $\pm$ )-1 (15 $\alpha$ -OH, more polar) and its 15 $\beta$ -OH isomer (less polar) respectively. The stereochemistry at C<sub>15</sub> was assigned tentatively according to the general rule.
12. All new compounds were characterized by <sup>1</sup>H-nmr and ir spectra and gave satisfactory elemental analyses and mass spectra. The spectral data and melting points (not corrected) of the final compound and selected intermediates are as follows: **18**: oil; ir (CHCl<sub>3</sub>) 1610, 1497, 1428, 1367, 1112, 820, 612 cm<sup>-1</sup>; nmr (CDCl<sub>3</sub>)  $\delta$  1.07 (9H, s), 1.40-2.13 (7H, m), 2.40-2.73 (1H, m), 2.73 (2H, t, J = 7 Hz), 3.36 (3H, s), 3.33-4.19 (9H, m), 4.69 (2H, s), 4.93 (1H, t, J = 7 Hz), 5.27-5.43 (1H, m), 5.70-5.94 (2H, m), 7.02 (2H, s), 7.13 (1H, s), 7.27-7.50 (6H, m), 7.60-7.86 (4H, m) ppm. **19**: oil; ir (CHCl<sub>3</sub>) 1489, 1428, 1113, 820, 612 cm<sup>-1</sup>; nmr (CDCl<sub>3</sub>)  $\delta$  0.74 (9H, s), 2.02 (1H, dq, J = 14 and 2 Hz), 2.35 (1H, ddd, J = 14, 9 and 4.5 Hz), 2.85 (2H, t, J = 7 Hz), 3.38 (3H, s), 3.50-3.77 (6H, m), 3.86-3.99 (2H, m), 4.25-4.32 (1H, m), 4.72 (2H, s), 5.21 (2H, d, J = 9 Hz), 6.66 (1H, d, J = 8 Hz), 6.94 (1H, dd, J = 8 and 2 Hz), 7.01 (1H, br s), 7.12-7.57 (15H, m) ppm. **21**: oil; ir (CHCl<sub>3</sub>) 3624, 1490, 1429, 1113, 919, 819, 612 cm<sup>-1</sup>; nmr (CDCl<sub>3</sub>)  $\delta$  0.85 (9H, s), 1.40 (1H, br s, OH), 1.78-2.20 (4H, m), 2.28-2.42 (1H, m), 2.79 (2H, t, J = 7 Hz), 3.72 (1H, td, J = 9 and 4 Hz), 3.79 (2H, t, J = 7 Hz), 3.92 (1H, q, J = 5 Hz), 4.82 (1H, dd, J = 9 and 3 Hz), 4.93 (1H, d, J = 12 Hz), 4.94 (1H, d, J = 16 Hz), 5.46-5.68 (1H, m), 6.71 (1H, d, J = 8 Hz), 6.94 (1H, d, J = 8 Hz), 6.98 (1H, s), 7.28-7.65 (10H, m) ppm. **1**: mp 122-123°C (EtOAc-n-hexane); ir (KBr) 3412, 3264, 2932, 2864, 1707, 1616, 1490, 1248, 1202, 970 cm<sup>-1</sup>; nmr (CD<sub>3</sub>OD)  $\delta$  0.92 (3H, t, J = 7 Hz), 1.20-1.75 (9H, m), 2.42-2.66 (2H, m), 3.50 (2H, s), 3.73 (1H, q, J = 9 Hz), 3.88 (1H, td, J = 9 and 6 Hz), 4.00-4.10 (1H, m), 4.85 (1H, dd, J = 9 and 7 Hz), 5.58-5.79 (2H, m), 6.66 (1H, d, J = 8 Hz), 7.00 (1H, dd, J = 8 and 2 Hz), 7.09 (1H, s) ppm.

Received, 7th March, 1990